PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibition
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-82724-w
Abstract: The overexpression of Polo-like kinase 1 (PLK1) is associated with poor clinical outcomes in various malignancies, making it an attractive target for anticancer therapies. Although recent studies suggest PLK1’s involvement in homologous recombination (HR), the… read more here.
Keywords: plk1 overexpression; sensitivity parp; homologous recombination; overexpression ... See more keywords